Led by an experienced team, CroíValve is developing a transcatheter device to treat Tricuspid Regurgitation; a progressive, debilitating disease affecting 550,000 patients annually. This is a significant unmet clinical need and a €3bn market opportunity.The CroiValve device offers improved patient outcomes and reduced healthcare costs. There is a well-defined route to market, and significant early acquisition predicates in the range $200-450M.